last
year
vaccin
sera
becom
avail
prophylaxi
treatment
diseas
preced
centuri
yet
time
number
obstacl
prevent
use
biomed
discoveri
benefit
mankind
risen
almost
proportion
stricter
regul
safeti
efficaci
led
increas
cost
product
biomed
secondli
price
consum
risen
degre
preclud
prophylact
vaccin
diseas
global
scale
addit
extraordinarili
high
price
new
vaccin
sera
method
administr
product
syring
needl
present
anoth
burden
worldwid
use
organ
mass
vaccin
trial
oral
polio
vaccin
belgian
congo
two
hundr
fifti
thousand
individu
vaccin
week
oral
spray
becam
model
worldwid
polio
vaccinationa
project
requir
one
oral
administr
productto
erad
polio
world
global
use
vaccin
requir
vaccin
inexpens
easili
maintain
distribut
consid
variou
altern
fulfil
criteria
establish
global
approach
immun
becom
clear
choic
product
vaccin
materi
biomed
import
plant
advantag
plant
quit
clear
plant
inexpens
grow
mass
grow
almost
soil
climat
world
variou
part
plant
leav
seed
fruit
chloroplast
also
use
vehicl
biomed
product
product
biomed
plant
administr
human
anim
also
provid
ad
margin
safeti
compar
biolog
produc
anim
tissu
earli
concern
plant
might
capabl
produc
biomed
anim
origin
plantspecif
glycosyl
pattern
might
function
alter
plantproduc
antibodi
proven
unwarr
basic
method
transfer
foreign
genes
plant
well
establish
first
approach
plant
transfect
foreign
gene
combin
plant
parasit
agrobacterium
tumefacien
constitut
approach
futur
gener
transgen
plant
speci
herit
retain
capac
express
origin
product
product
isol
extract
leav
seed
etc
tabl
second
approach
gene
insert
plant
viru
exampl
alfalfa
tobacco
mosaic
viru
use
combin
foreign
antigen
infect
plant
final
product
harvest
plant
tandem
plant
viru
case
purif
vaccin
antibodi
rather
simpl
procedur
achiev
product
plantderiv
vaccin
sera
classifi
two
categori
vaccin
antibodi
infecti
diseas
vaccin
antibodi
cancer
tabl
show
list
infecti
diseas
agent
plantderiv
product
made
biotechnolog
foundat
laboratori
chronolog
order
respiratori
syncyti
viru
rsv
hepat
b
hiv
rabi
anthrax
diphtheria
sar
smallpox
viru
one
first
vaccin
produc
system
rsv
caus
diseas
newborn
children
produc
vaccin
antigen
fusion
protein
capsid
protein
alfalfa
mosaic
viru
tobacco
immunogen
test
mice
either
inject
fed
plantproduc
vaccin
compar
control
hightit
antibodi
rsv
also
induc
plantderiv
vaccin
hiv
anthrax
present
dr
alexand
karasev
scientist
leadership
professor
andrzej
legocki
poznan
poland
produc
vaccin
hepat
b
transgen
lettuc
scientist
shown
vaccin
express
lettuc
leav
ground
frozen
dri
powder
without
loss
immunogen
observ
immun
respons
mice
fed
plantderiv
vaccin
indic
two
feed
interv
produc
optim
immunogen
respons
rabi
worldwid
diseas
human
warmblood
anim
except
timehonor
pasteur
type
vaccin
modern
vaccin
expens
use
worldwid
scale
rabi
antibodi
essenti
treat
sever
bite
unavail
suffici
lucr
product
pharmaceut
industri
rabi
dog
major
uniqu
sourc
infect
southeast
asia
mani
african
countri
inexpens
bait
vaccin
dog
could
lead
erad
rabi
part
world
express
rabi
vaccin
plant
use
recombin
alfalfa
mosaic
viru
spinach
leav
viru
express
chimer
peptid
contain
antigen
determin
rabi
viru
glycoprotein
elicit
immun
respons
nucleoprotein
increas
glycoprotein
immunogen
chimer
gene
antigen
pcramplifi
clone
fusion
gene
encod
coat
protein
alfalfa
mosaic
viru
tobacco
spinach
plant
use
express
antigen
presenc
rabi
viru
protein
spinach
leav
check
western
blot
immunogen
test
mice
volunt
fed
g
spinach
extract
recombin
viru
twice
interv
half
subject
respond
oral
administr
spinach
indic
vigor
booster
respons
singl
inject
commerci
vaccin
global
crisi
postexposur
treatment
rabi
worldwid
unavail
antirabi
serum
requir
sever
bite
thu
decid
emerg
basi
produc
rabi
antibodi
plant
research
conduct
dr
kisung
ko
led
product
transgen
tobacco
plant
contain
heavi
light
chain
human
rabi
antibodi
two
chain
recombin
plant
produc
complet
antirabi
antibodi
effect
origin
antibodi
anim
exposur
rabi
tabl
two
interest
result
emerg
research
antibodi
first
leaf
extract
transgen
tobacco
found
virtual
free
nicotin
alkaloid
fig
second
glycosyl
pattern
plantderiv
antibodi
consider
differ
anim
tissuederiv
antibodi
fig
mannos
glycan
preval
plantibodi
yet
antibodi
least
efficaci
nativ
antibodi
produc
anim
tabl
vivo
efficaci
mab
p
postexposur
prophylaxi
hamster
inject
lethal
dose
coyot
rabi
street
virus
dr
c
rupprecht
cdc
postexposur
treatment
antibodi
iuanim
vaccin
hdcv
b
mab
p
c
mab
p
mab
p
hrig
untreat
control
ko
et
al
pna
iu
intern
unit
b
hdcv
imovax
lot
human
diploid
cell
cultur
rabi
viru
vaccin
indic
treatment
without
hdcv
respect
c
number
surviv
hamstersnumb
hamster
test
strict
guidelin
regard
amount
potenc
antirabi
antibodi
use
postexposur
treatment
enabl
calculationbas
yield
antibodi
per
tobacco
plantof
plant
acreag
need
produc
given
number
antibodi
intern
unit
expect
kg
tobacco
produc
mg
antibodi
ha
acr
need
produc
enough
antibodi
vaccin
peopl
leav
account
calcul
product
cost
antibodi
compar
antibodi
produc
anim
tissu
one
mani
advantag
plant
product
biolog
product
abil
express
multipl
gene
plant
vaccin
diphtheria
tetanu
oral
pertussi
triad
inject
infant
first
month
life
plan
substitut
oral
product
inject
vaccin
initi
product
transgen
tobacco
model
transgen
carrot
express
three
vaccin
tabl
plant
express
current
diphtheria
toxoid
alreadi
produc
fig
spike
protein
sar
coronaviru
presum
immunogen
transgen
tobacco
tomato
express
spike
protein
gener
fig
interestingli
month
elaps
introduct
spike
construct
plant
first
observ
sar
coronaviru
mrna
express
plant
fig
theoret
vaccin
could
obtain
grow
larg
number
transgen
plant
doubt
whether
method
current
avail
would
produc
vaccin
materi
newli
discov
diseas
short
time
decad
neglect
wit
reviv
interest
immunolog
approach
cancer
treatment
thu
sought
express
colorect
cancer
antigen
ga
correspond
antibodi
plant
attempt
also
made
express
antibodi
recogn
epiderm
growth
factor
egf
present
surfac
epitheli
tumor
plant
tobacco
mosaic
virusbas
gene
vector
use
express
ga
antigen
nicotiana
betthamiana
infect
construct
check
express
western
blot
analysi
leaf
extract
group
mice
immun
plantproduc
antigen
comparison
anoth
group
antigen
express
baculoviru
system
sera
obtain
group
mice
recogn
human
colorect
cell
line
express
antigen
fig
cross
reactiv
test
capabl
discrimin
two
antigen
produc
plant
produc
baculoviru
vector
rule
contamin
basi
immun
respons
complementdepend
cytotox
assay
sera
obtain
mice
immun
plantderiv
antigen
show
lysi
breast
cancer
cell
antigen
unrel
melanoma
cell
fig
plantderiv
antigen
also
induc
antigenspecif
prolifer
cell
use
techniqu
antirabi
antibodi
express
antibodi
tobacco
plant
purifi
leaf
extract
plant
specif
recogn
receptor
present
human
colorect
cancer
cell
perhap
interest
result
obtain
studi
two
plantibodi
rabi
cancer
relat
glycosyl
pattern
plantderiv
antirabi
heavi
chain
fuse
kdel
lysineasperagineglycosamineleucin
endoplasm
reticulum
retent
signal
result
antirabi
plantibodi
contain
abund
mannos
wherea
plantderiv
anticanc
antibodi
contain
less
mannos
nacetylglucosamin
fig
despit
differ
glycosyl
pattern
two
plantibodi
differ
pattern
nativ
antibodi
biolog
activ
equival
nativ
antibodi
antibodi
reactiv
epiderm
growth
factor
recent
licens
treat
certain
type
epitheli
cancer
antibodi
first
develop
wistar
institut
mani
year
ago
recent
adapt
product
tobacco
plant
within
near
futur
might
provid
inexpens
therapeut
tool
human
cancer
howev
plant
product
vaccin
sera
simpl
procedur
assur
success
undertak
one
import
remain
problem
low
yield
bioproduct
plant
date
magic
solut
problem
found
codon
optim
care
approach
harvest
purifi
plant
product
use
plant
part
chloroplast
increas
uptak
materi
potenti
avenu
help
increas
yield
final
product
present
still
difficult
produc
sizeabl
amount
plantderiv
product
great
stride
made
knowledg
expertis
use
plant
host
product
biomed
tabl
four
stage
adopt
new
idea
first
imposs
second
mayb
possibl
weak
uninterest
third
true
told
fourth
thought
first
shown
last
tabl
tabl
segment
popul
remain
convinc
futur
biolog
link
product
plant
peopl
consid
fact
ultim
opt
accept
other
remain
true
believ
harm
effect
caus
transgen
plant
voic
may
becom
subdu
even
silenc
increas
evid
futur
global
health
improv
rest
strictli
progress
made
worldwid
use
plant
combat
diseas
